In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas.
- H Matsuoka
- Y Shibamoto
- T Kubota
- M Tsujitani
- T Majima
Affiliations: Clinical Research Institute, National Kyushu Cancer Center, Fukuoka 811-1347, Japan.
- Published online on: January 1, 2000 https://doi.org/10.3892/or.7.1.23
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
A new 2-nitroimidazole radiosensitizer doranidazole is now undergoing clinical evaluation in combination with intraoperative radiotherapy for unresectable pancreatic cancer. However, there have been no laboratory data on its effect against pancreatic cancer. This study was undertaken to clarify the efficacy and pharmacokinetics of doranidazole in a human pancreatic cancer SUIT-2 xenografted in the pancreas of nude mice. The tumor-bearing mice were irradiated to the upper abdomen using electron beams with or without prior administration of doranidazole. The tumors were excised 3-6 days later and their weight was measured. Doranidazole given alone had no antitumor effect, but it had radiosensitizing effects when 100, 150, or 200 mg/kg of the drug was combined with single 5 Gy irradiation. The tumor/serum ratios for doranidazole concentration were 0.3-0.4, but the concentrations in the tumor were similar to those in the surrounding normal pancreas. At doses of 100 mg/kg or higher, concentrations of doranidazole in the pancreatic tumor appeared to be sufficient to obtain definite radiosensitization.